Brief treatment with iNKT cell ligand α-galactosylceramide confers a long-term protection against lupus

Journal of Clinical Immunology

Volumn 32, Issue 1, 2012, Pages 106-113

  Yang, Jun Qi ^a,b,c   Kim, Peter J ^a   Singh, Ram Raj ^a,b,d,e  

^a Division of Rheumatology   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c JIANGSU INSTITUTE OF PARASITIC DISEASES   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoimmunity; Rodent; Systemic lupus erythematosus; T cells

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; ALPHA GALACTOSYLCERAMIDE; INTERLEUKIN 10; ALPHA-GALACTOSYLCERAMIDE; CYTOKINE; GALACTOSYLCERAMIDE; LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INJECTION; LONG TERM CARE; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DISEASE MODEL; FEMALE; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; NEW ZEALAND BLACK MOUSE; PROTEINURIA;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GALACTOSYLCERAMIDES; INTERLEUKIN-10; LIGANDS; LUPUS NEPHRITIS; MICE; MICE, INBRED BALB C; MICE, INBRED NZB; MICE, KNOCKOUT; MICE, SCID; NATURAL KILLER T-CELLS; PROTEINURIA;

EID: 84862246208     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-011-9590-y     Document Type: Article

References (36)

1. Bendelac A. CD1: presenting unusual antigens to unusual T lymphocytes. Science. 1995;269:185-6.
2. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol. 2004;4:231-7. (Pubitemid 38339089)
3. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol. 2005;23:877-900. (Pubitemid 40563188)
4. Yang JQ, Wen X, Kim PJ, Singh RR. Invariant NKT cells inhibit autoreactive B cells in a contact-and CD1d-dependent manner. J Immunol. 2011;186:1512-20.
5. Yang JQ, Wen X, Liu H, Folayan G, Dong X, Zhou M, et al. Examining the role of CD1d and natural killer T cells in the development of nephritis in a genetically susceptible lupus model. Arthritis Rheum. 2007;56:1219-33. (Pubitemid 46608647)
6. F. Wermeling, S.M. Lind, E.D. Jordo, S.L. Cardell, M.C. Karlsson, Invariant NKT cells limit activation of autoreactive CD1d-positive B cells. J Exp Med. 2010;207:943-52.
7. Wither J, Cai YC, Lim S, McKenzie T, Roslin N, Claudio JO, et al. Reduced proportions of natural killer T cells are present in the relatives of lupus patients and are associated with autoimmunity. Arthritis Res Ther. 2008;10:R108.
8. Kojo S, Adachi Y, Keino H, Taniguchi M, Sumida T. Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum. 2001;44:1127-38. (Pubitemid 32433619)
9. van der Vliet HJ, von Blomberg BM, Nishi N, Reijm M, Voskuyl AE, van Bodegraven AA, et al. Circulating V(alpha24+) Vbeta11 + NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin Immunol. 2001;100:144-8.
10. Oishi Y, Sumida T, Sakamoto A, Kita Y, Kurasawa K, Nawata Y, et al. Selective reduction and recovery of invariant Vα24 JαQT cell receptor T cells in correlation with disease activity in patients with systemic lupus erythematosus. J Rheumatol. 2001;28:275-83. (Pubitemid 32165132)
11. Hahn BH, Singh RR. Animal models of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus, Lippincott. Philadelphia: Williams and Wilkins; 2007. p. 299-355.
12. Bendelac A, Hunziker RD, Lantz O. Increased interleukin 4 and immunoglobulin E production in transgenic mice overexpressing NK1 T cells. J Exp Med. 1996;184:1285-93. (Pubitemid 26354684)
13. Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, et al. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science. 1997;278:1623-6. (Pubitemid 27516281)
14. Fan GC, Singh RR. Vaccination with minigenes encoding V(H)derived major histocompatibility complex class I-binding epitopes activates cytotoxic T cells that ablate autoantibody-producing B cells and inhibit lupus. J Exp Med. 2002;196:731-41.
15. Yang JQ, Singh AK, Wilson MT, Satoh M, Stanic AK, Park JJ, et al. Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis. J Immunol. 2003;171:2142-53. (Pubitemid 36966498)
16. Yang JQ, Saxena V, Xu H, Van Kaer L, Wang CR, Singh RR. Repeated alpha-galactosylceramide administration results in expansion of NK T cells and alleviates inflammatory dermatitis in MRL-lpr/lpr mice. J Immunol. 2003;171:4439-46. (Pubitemid 37238724)
17. Van Kaer L. alpha-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat Rev Immunol. 2005;5:31-42. (Pubitemid 40070329)
18. Major AS, Singh RR, Joyce S, Van Kaer L. The role of invariant natural killer T cells in lupus and atherogenesis. Immunol Res. 2006;34:49-66. (Pubitemid 43780376)
19. Coppieters K, Van Beneden K, Jacques P, Dewint P, Vervloet A, Vander Cruyssen B, et al. A single early activation of invariant NK T cells confers long-term protection against collagen-induced arthritis in a ligand-specific manner. J Immunol. 2007;179:2300-9.
20. Dombrowicz D. Exploiting the innate immune system to control allergic asthma. Eur J Immunol. 2005;35:2786-8. (Pubitemid 41555074)
21. Morishima Y, Ishii Y, Kimura T, Shibuya A, Shibuya K, Hegab AE, et al. Suppression of eosinophilic airway inflammation by treatment with alpha-galactosylceramide. Eur J Immunol. 2005;35:2803-14. (Pubitemid 41555077)
22. Yang JQ, Chun T, Liu H, Hong S, Bui H, Van Kaer L, et al. CD1d deficiency exacerbates inflammatory dermatitis in MRL-lpr/lpr mice. Eur J Immunol. 2004;34:1723-32. (Pubitemid 39256055)
23. Singh AK, Yang JQ, Parekh VV, Wei J, Wang CR, Joyce S, et al. The natural killer T cell ligand alpha-galactosylceramide prevents or promotes pristane-induced lupus in mice. Eur J Immunol. 2005;35:1143-54. (Pubitemid 40542221)
24. Sireci G, Russo D, Dieli F, Porcelli SA, Taniguchi M, La Manna MP, et al. Immunoregulatory role of Jalpha281 T cells in aged mice developing lupus-like nephritis. Eur J Immunol. 2007;37:425-33. (Pubitemid 46915582)
25. Zeng D, Lee MK, Tung J, Brendolan A, Strober S. Cutting edge: a role for CD1 in the pathogenesis of lupus in NZB/NZW mice. J Immunol. 2000;164:5000-4. (Pubitemid 30305168)
26. Zeng D, Liu Y, Sidobre S, Kronenberg M, Strober S. Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J Clin Invest. 2003;112:1211-22. (Pubitemid 38056298)
27. Morshed SR, Takahashi T, Savage PB, Kambham N, Strober S. Beta-galactosylceramide alters invariant natural killer T cell function and is effective treatment for lupus. Clin Immunol. 2009;132:321-33.
28. Chiba A, Kaieda S, Oki S, Yamamura T, Miyake S. The involvement of V(alpha)14 natural killer T cells in the pathogenesis of arthritis in murine models. Arthritis Rheum. 2005;52:1941-8. (Pubitemid 40852903)
29. Chiba A, Oki S, Miyamoto K, Hashimoto H, Yamamura T, Miyake S. Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of alpha-galactosylceramide. Arthritis Rheum. 2004;50:305-13. (Pubitemid 38084316)
30. Jahng AW, Maricic I, Pedersen B, Burdin N, Naidenko O, Kronenberg M, et al. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med. 2001;194:1789-99. (Pubitemid 34028658)
31. Van Kaer L. Natural killer T cells as targets for immunotherapy of autoimmune diseases. Immunol Cell Biol. 2004;82:315-22. (Pubitemid 38870026)
32. Furlan R, Bergami A, Cantarella D, Brambilla E, Taniguchi M, Dellabona P, et al. Activation of invariant NKT cells by alphaGalCer administration protects mice from MOG35-55induced EAE: critical roles for administration route and IFN-gamma. Eur J Immunol. 2003;33:1830-8. (Pubitemid 37120854)
33. Singh AK, Wilson MT, Hong S, Olivares-Villagomez D, Du C, Stanic AK, et al. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med. 2001;194:1801-11. (Pubitemid 34028659)
34. Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med. 1995;181:839-44.
35. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med. 1994;179:305-10. (Pubitemid 24012996)
36. Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH, et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 2000;43:1790-800.